The Spleen in Sickle Cell Anemia and Sickle Cell Thalassemia

The Spleen in Sickle Cell Anemia and Sickle Cell Thalassemia. Clinical Presentation and Follow up. Splenectomy, Indications and Complications.


Lead Sponsor: HaEmek Medical Center, Israel

Source HaEmek Medical Center, Israel
Brief Summary

The spleen in Sickle Cell Anemia and Sickle Cell Thalassemia is usually enlarged in the first years of life but the immune protection provided is considered insufficient. In homozygous Sickle cell patients the spleen usually developed recurrent infarcts and after the first decade of age become fibrotic. Acute splenic sequestration is also frequent in those patients and this is considered as an indication for splenectomy.

In comparison in Sickle cell thalassemia patients, hypersplenism is more frequent.

The purpose of this study is to compare the clinical and laboratory issues related to the spleen in two groups of Sickle cell patients.

Detailed Description

Clinical and laboratory characteristics related to the spleen in SCA patients will be studied.

Two groups of patient will be compared, a group of Sickle cell patients (Homozygous) and a second group of patients with Sickle cell beta thalassemia.

In those patients that splenectomy was performed the incidence of infections will be recorded besides the indications for splenectomy and the incidence of thrombotic events or thrombocytosis.

Overall Status Completed
Start Date February 2009
Completion Date August 2010
Primary Completion Date August 2010
Study Type Observational
Primary Outcome
Measure Time Frame
Clinical events and abnormal laboratory results One year
Enrollment 50

Sampling Method: Probability Sample


Inclusion Criteria:

- All the patients followed up at the Pediatric Hematology Unit

Exclusion Criteria:

- Patients lost from follow up of with insufficient data

Gender: All

Minimum Age: 1 Year

Maximum Age: 35 Years

Healthy Volunteers: No

Facility: Pediatric Hematology Unit and Pediatric Dpt B - HaEmek Medical Center
Location Countries


Verification Date

August 2011

Responsible Party

Type: Principal Investigator

Investigator Affiliation: HaEmek Medical Center, Israel

Investigator Full Name: Dr Koren Ariel

Investigator Title: Head of Pediatric Hematology Unit and Pediatric Dpt B

Has Expanded Access No
Condition Browse
Arm Group

Label: Sickle Cell Patients

Description: Patients with homozygous Sickle Cell Anemia

Label: Sickle Cell Thalassemia

Description: Patients with Sickle Cell Thalassemia

Study Design Info

Observational Model: Cohort

Time Perspective: Retrospective